IMUX Logo

Immunic, Inc. (IMUX) 

NASDAQ
Market Cap
$108.09M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
304 of 776
Rank in Industry
178 of 433

Largest Insider Buys in Sector

IMUX Stock Price History Chart

IMUX Stock Performance

About Immunic, Inc.

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the …

Insider Activity of Immunic, Inc.

Over the last 12 months, insiders at Immunic, Inc. have bought $18,333 and sold $0 worth of Immunic, Inc. stock.

On average, over the past 5 years, insiders at Immunic, Inc. have bought $111,735 and sold $205,490 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Vitt Daniel (President and CEO) — $18,333.

The last purchase of 14,000 shares for transaction amount of $18,333 was made by Vitt Daniel (President and CEO) on 2024‑02‑26.

List of Insider Buy and Sell Transactions, Immunic, Inc.

2024-02-26PurchasePresident and CEO
14,000
0.0159%
$1.31$18,333+3.91%
2023-05-15PurchaseChief Financial Officer
5,000
0.0114%
$1.75$8,750-22.16%
2022-12-14Purchasedirector
47,000
0.1472%
$1.26$59,032+28.97%
2022-12-13Purchasedirector
35,000
0.1105%
$1.25$43,610+31.05%
2022-11-23Purchasedirector
18,000
0.0578%
$1.39$25,020+19.85%
2022-11-22PurchasePresident and CEO
8,000
0.0259%
$1.35$10,799+24.05%
2022-11-07PurchaseChief Financial Officer
5,000
0.0164%
$1.50$7,475+13.64%
2022-06-03PurchasePresident and CEO
5,000
0.0151%
$3.10$15,500-43.22%
2022-06-03PurchaseChief Financial Officer
3,500
0.0104%
$3.04$10,658-43.22%
2022-05-12PurchaseChief Medical Officer
3,500
0.0115%
$5.10$17,850-59.81%
2022-05-12PurchaseExecutive Chairman
10,000
0.0323%
$5.03$50,300-59.81%
2022-05-12PurchaseChief Financial Officer
3,000
0.0098%
$5.08$15,240-59.81%
2021-08-10PurchasePresident and CEO
1,000
0.0039%
$9.60$9,600-5.42%
2021-08-10PurchaseExecutive Chairman
1,000
0.004%
$9.80$9,800-5.42%
2021-08-10PurchasePFO and PAO
1,500
0.006%
$9.85$14,775-5.42%
2021-05-12PurchaseExecutive Chairman
4,000
0.0186%
$12.75$51,000-21.89%
2021-03-02PurchaseChief Medical Officer
10,006
0.046%
$15.54$155,493-34.17%
2021-03-02PurchasePFO and PAO
1,000
0.0049%
$16.48$16,480-34.17%
2020-08-10PurchasePFO and PAO
1,000
0.0051%
$18.96$18,960-20.03%
2020-07-21SaleChief Executive Officer
1,300
0.0067%
$15.62$20,310-1.12%

Insider Historical Profitability

39.15%
Vitt DanielPresident and CEO
390877
0.4339%
$1.2042<0.0001%
Muehler AndreasChief Medical Officer
297986
0.3308%
$1.2020<0.0001%
Winters Terence E.Co-Chairman and CEO
194966
0.2164%
$1.2020+75.81%
Neermann Joergdirector
100000
0.111%
$1.2030+26.62%
SEARS LOWELLdirector
58572
0.065%
$1.2020

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Avidity Partners Management Lp$11.75M9.888.9MNew+$11.75M0.45
Bvf Inc Il$11.75M9.888.9MNew+$11.75M0.09
Soleus Capital Management, L.P.$9.63M8.17.29M+2,331%+$9.23M0.04
Janus Henderson$9.27M7.766.99MNew+$9.27M0.01
Adage Capital Partners Gp L L C$7.38M6.215.59MNew+$7.38M0.01
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.